Investigators at Kobe Minimally Invasive Cancer Center Report Findings in Non-Small Cell Lung Cancer (Afatinib Plus Bevacizumab Combination After Osimertinib Resistance In Advanced Egfr-mutant Non-small Cell Lung Cancer: Phase Ii...).

Researchers at the Kobe Minimally Invasive Cancer Center in Japan conducted a study on non-small cell lung cancer patients who developed resistance to osimertinib. They found that a combination of afatinib and bevacizumab showed clinical efficacy in these patients. The study analyzed gene alterations and identified various resistant mechanisms in the patients. The researchers concluded that selected patients could benefit from this combination therapy after developing resistance to osimertinib. [Extracted from the article]